SCHEMBL4822006

SCHEMBL4822006

Cn1c(C(=O)N[C@H]2CCCC[C@H]2C(=O)NCC=O)cc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.47
▸ GHSR Q92847 2/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ CNR2 P34972 1/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ MCL1 Q07820 1/20 0.41
▸ CCKAR P32238 3/20 0.41
▸ CCKBR P32239 3/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4823902 0.88 CHRNA7 (0.47) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL8251025 0.88 CNR2 (0.50) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL4826756 0.88 CHRNA7 (0.47) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL4824939 0.87 MEN1 (0.46) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL4825563 0.87 CHRNA7 (0.46) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL5259022 0.87 CHRNA7 (0.46) CHRNA7GHSRKCNH2CNR2HDAC1
SCHEMBL4822931 0.87 MEN1 (0.45) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL4823738 0.86 CHRNA7 (0.46) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL14193441 0.86 CHRNA7 (0.51) CHRNA7GHSRKCNH2CNR2MEN1
SCHEMBL4825471 0.86 CHRNA7 (0.46) CHRNA7GHSRKCNH2CNR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7358373-B2 Cathepsin K inhibitors ROCHE PALO ALTO LLC (US) 2008-04-15 — — US disclosed
US-7358373-B2 Cathepsin K inhibitors ROCHE PALO ALTO LLC (US) 2008-04-15 — — US disclosed
US-7358373-B2 Cathepsin K inhibitors ROCHE PALO ALTO LLC (US) 2008-04-15 — — US disclosed
US-20070032484-A1 Cathepsin K inhibitors ROCHE PALO ALTO LLC 2007-02-08 — — US disclosed
US-20070032484-A1 Cathepsin K inhibitors ROCHE PALO ALTO LLC 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032484-A1 Cathepsin K inhibitors CTSK, CTSS, CTSF CHRNA7 3660/4885GHSR 686/4885KCNH2 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback